A Phase 2, Randomized, Double-blind, Placebo-controlled, Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Latest Information Update: 15 Dec 2021
At a glance
- Drugs Tenapanor (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Kyowa Kirin
Most Recent Events
- 12 Oct 2020 According to an Ardelyx media release, data from this trial will be presented at Kidney Week 2020, the American Society of Nephrology's (ASN) Annual Meeting.
- 14 Jan 2020 Status changed from recruiting to completed.
- 10 Jun 2019 Status changed from not yet recruiting to recruiting.